Status:
COMPLETED
A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer
Lead Sponsor:
AbbVie
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases of which 60% are non-squamous (NSQ). This study will evaluate the prevalence of ...
Eligibility Criteria
Inclusion
- Previously consented and/or prospective collection of consent for research use of banked biological materials and clinical data.
- Confirmed advanced and/or metastatic non-squamous (NSQ) non-small cell lung cancer (NSCLC).
- Has formalin-fixed paraffin-embedded (FFPE) tissue collected since 2019.
Exclusion
- Specimens collected before 2019.
- Insufficient specimen tissue for testing.
- Insufficient specimen quality (e.g., not 4-5 µm in thickness) which precludes testing.
- Adenosquamous and sarcomatous histologies of NSCLC.
Key Trial Info
Start Date :
November 3 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
579 Patients enrolled
Trial Details
Trial ID
NCT06068842
Start Date
November 3 2023
End Date
December 31 2024
Last Update
January 29 2025
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Italiano de Buenos Aires /ID# 256999
Ciudad Autonoma Buenos Aires, Buenos Aires F.D., Argentina, 1199
2
Instituto Alexander Fleming /ID# 256295
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina, 1426
3
Irmandade da Santa Casa de Misericordia de Porto Alegre /ID# 256487
Porto Alegre, Rio Grande do Sul, Brazil, 90020-090
4
Hospital Alemao Oswaldo Cruz /ID# 256486
São Paulo, Brazil, 01323-020